A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours

Richard Wilson, P. Hari Dass, Sandra Van Schaeybroeck, Elena Elez, A Quinton, R. Jones, Jennifer Houlden, Linda Collins, C Roberts, Sharon Love, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, alberto Bardelli, Pierre Laurent=puig, Tim Maughan, Josef Tabernero, Marc Peeters, Mark Middleton, Christian Rolfo

Research output: Contribution to journalMeeting abstract

Original languageEnglish
Pages (from-to)e140-e141
JournalEuropean Journal of Cancer
Volume103
Issue numberSuppl 1
Publication statusPublished - Nov 2018

Cite this

Wilson, R., Dass, P. H., Van Schaeybroeck, S., Elez, E., Quinton, A., Jones, R., Houlden, J., Collins, L., Roberts, C., Love, S., Lawler, M., Di Nicolantonio, F., Grayson, M., Bardelli, A., Laurent=puig, P., Maughan, T., Tabernero, J., Peeters, M., Middleton, M., & Rolfo, C. (2018). A phase I dose escalation multi-centre study of crizotinib (MET inhibitor) combined with binimetinib (MEK inhibitor) in patients with advanced solid tumours. European Journal of Cancer, 103(Suppl 1), e140-e141. https://www.sciencedirect.com/journal/european-journal-of-cancer/vol/103/suppl/S1